ARO-ANG3
- Generic Name
- ARO-ANG3
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
ARO-ANG3 is a subcutaneously administered RNA interference (RNAi)-based investigational medicine targeting angiopoietin-like protein 3 (ANGPTL3). It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia (HoFH).
- Associated Conditions
- -
- Associated Therapies
- -
Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 204
- Registration Number
- NCT04832971
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸AGA Clinical Trials, Hialeah, Florida, United States
🇺🇸Medication Management LLC, Greensboro, North Carolina, United States
Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 93
- Registration Number
- NCT03747224
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Australia
🇳🇿Auckland Clinical Studies Limited, Grafton, Auckland, New Zealand
🇳🇿Middlemore Hospital, Papatoetoe, Aukland, New Zealand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath